MacroGenics aims its enhanced antibodies at annihilating diseased cells. The company is developing therapeutic treatments for cancer, autoimmune disorders, and infectious diseases. The company is helping researchers from National Institutes of Health and two universities to develop a fully human monoclonal antibody (single disease-cell targeting protein) treatment for the deadly West Nile virus. MacroGenics is also in late development stages for another monoclonal antibody used to treat Type 1 diabetes (also known as juvenile diabetes); the diabetes treatment has received orphan drug status, an FDA designation for rare diseases. Other targeted ailments include cancer, arthritis, and multiple sclerosis.